INSIGHTS ON ENTERPRISE SOLUTIONS
-
Periodic Counter-Current Chromatography
Batch chromatography leaves resin capacity unused to stay clear of breakthrough; cycling columns puts it to work, but resin and feed variability make holding breakthrough steady the real test.
-
Why Robust Microbial Ingress Testing Matters
Explore why robust microbial ingress testing is essential for evaluating the sterile-barrier performance of single-use connectors during connection, disconnection, and other dynamic handling conditions.
-
The Environmental Case For Single-Use Systems
Discover how life-cycle assessments reveal the hidden resource and energy burdens of equipment cleaning versus single-use systems in modern pharmaceutical production facilities.
-
The Case For Distributed Manufacturing With CTMC's Jason Bock, Ph.D.
In this episode of “Better Biopharma,” host Tyler Menichiello is joined by Jason Bock, Ph.D., founder and CEO of CTMC, to discuss the logistics and operational nuance of distributed hub-and-spoke manufacturing models for cell therapies.
-
Decoding Biologics Tech Transfer: Process Performance Across Sites And Scales11/16/2026
Explore how bioreactor modeling, equipment characterization, and process science can address scale-up challenges and maintain biologics performance across sites, scales, and bioreactor systems.
-
Set Your Own Intensity: When Economics Drives The Decision11/13/2026
Process intensification has no universal lowest-cost architecture. The right economic choice follows the manufacturing constraint, and it can shift as demand, scale, and productivity limits change.
-
Set Your Own Intensity: When Flexibility Matters Most11/13/2026
Intensifying one operation often shifts the constraint to another. Real flexibility depends on designing cadence, capacity, connections, and control, and on choosing how connected a workflow should be.
-
Set Your Own Intensity: When You Need More Output11/13/2026
Raising bioreactor output without adding vessel size means choosing between strategies, then confirming that harvest, capture, and purification can absorb the additional product.
ENTERPRISE SOLUTIONS
-
A single coordinated program for sterile liquid vial tech transfer commits to a GMP Phase III clinical batch in 26 weeks, with the timeline backed by a pay-for-performance guarantee.
-
Sterile drug product manufacturing works as a cohesive, closed workflow, not a set of individual components. Sterility, integrity, and compliance must hold from formulation through final filtration.
-
Unused Cytiva ÄKTA ready single-use chromatography system, serial# 2965532, built 2022
-
Custom nanoparticle development and cGMP manufacturing for medical applications are specialized work that few contract partners attempt, spanning the path from preclinical studies to commercialization.
-
A single partner carries nanomedicine programs from screening to clinical supply across lipid, polymeric, and metal-based particles, with precursor manufacturing newly added to the lineup.